Editorials

Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis? J.M. Kremer 2217
The Difficult Task of Assessing Psoriatic Arthritis A. Caull, M. Piga 2219

Articles

A Study of Multiple Causes of Death in RA F.A. Pinheiro, D.C. Souza, E.I. Sato 2221
The Risk of TB in Patients with RA Treated with TNF-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies J.W. Ai, S. Zhang, Q.L. Ruan, et al. 2229
Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with RA in Remission: A CORRONA and NinJa Collaborative Cohort Study K. Yoshida, H. Radner, M.D. Mjaavatten, et al. 2238
RA: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden A.B. Pedersen, A. Mor, F. Mehnert, R.W. Thomsen, S.P. Johnsen, M. Nørgaard 2247
Concomitant MTX Protects Against TKA in Patients with RA Treated with TNF Inhibitors S. Asai, N. Takahashi, K. Funahashi, et al. 2255
Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in RA: A Systematic Review and Metaanalysis C. Vidal, T. Barnetche, J. Morel, B. Combe, C. Daïen 2261
Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol M.E. Clowse, D.C. Wolf, F. Förger, et al. 2270
Clinical and Radiographic Outcomes in Patients Diagnosed with Early RA in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study G. Haugeberg, P. Bayesén, K. Helgetveit, A. Prøven 2279
A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset SLE M.F. Silva, M.P. Ferriani, M.T. Terreri, et al. 2296
Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset SLE Y. Yang, S. Kumar, L.S. Lim, E.D. Silverman, D.M. Levy 2304
Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort L. Sáez-Comet, C.P. Simeón-Aznar, M. Pérez-Conesa, et al, and the RESCLE Investigators 2327
Patient’s Global Assessment as an Outcome Measure for PsA in Clinical Practice: A Surrogate for Measuring Low Disease Activity? E. Lubrano, F.M. Perrotta, W.J. Parsons, A. Marchesoni 2332
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study A.V. Heinonen, K.J. Aaltonen, J.T. Joensuu, et al. 2339
Fatigue in Ankylosing Spondylitis and Nonradiographic AxSpA: Analysis from a Longitudinal Observation Cohort M. Bedaiwi, I. Sari, A. Thavaneswaran, R. Ayeaest, N. Haroon, R.D. Inman 2354
Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antinflammatory Drug-sparing Endpoints, Alone or in Combination, in AxSpA M. Dougados, E. Wood, L. Gossec, A. Dubanchet, I. Logeat, D. van der Heijde 2361
Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls S. van Genderen, A. Boonen, D. van der Heijde, et al. 2369
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the USA K. Raimundo, A.M. Farr, G. Kim, G. Duna 2383
Knee Pain Patterns and Associations with Pain and Function in Persons with or at Risk for Symptomatic Radiographic OA: A Cross-sectional Analysis  D.L. Riddle, M. Makowski .................. 2398
Evaluating Disease Severity in Chronic Pain Patients with and without FM: A Comparison of the Symptom Impact Questionnaire and the Polysymptomatic Distress Scale R. Friend, R.M. Bennett .................. 2404

Pediatric Rheumatology
Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with JDM  N. Kobayashi, I. Kobayashi, M. Mori, et al .................. 2412
Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls H. Schmeling, M. Mahler, D.M. Levy, et al .................. 2419

Images in Rheumatology
Maffucci Syndrome Y.P. Tsao, C.Y. Tsai, W.S. Chen .................. 2434

OMERACT 12 — International Consensus Conference on Outcome Measures in Rheumatology, Budapest, Hungary, May 7-11, 2014

Special Interest Groups I

Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group R. Grainger, N. Dalbeth, H. Keen, et al .................. 2460
Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12 S.Z. Aydin, H. Direskeneli, A. Strei, et al .................. 2465
Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial D. Gilnatisi, P. Bird, F. Gandjibakhch, et al .................. 2473
Outcome Domains and Measures in TJR Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative J.A. Singh, M. Dohm, A.P. Sprowson, et al .................. 2496
Outcome Measures in Polymyalgia Rheumatica. A Systematic Review C. Duarte, R.J. Ferreira, S.L. Mackie, J.R. Kirwan, J.A. Pereira de Silva, on behalf of the OMERACT Polymyalgia Rheumatica Special Interest Group .................. 2503

Correspondence
Specificity of Systemic Sclerosis Classification Criteria M. Baron, J.E. Pope, F. van den Hoogen, et al .................. 2512
Reply A.M. Hoffmann-Vold .................. 2513
Reply D. Fan, L. Xin, L. Liu, G. Cai, S. Xu, F. Pan .................. 2514

Letter
Diagnostic Challenges of SAPHO Syndrome M. Colina .................. 2514
Reviewer Index .................. 2516
Content Index .................. 2518
Meetings in Rheumatology